Roche Holding company profile
Company profile
Roche Holding has 103,249 employees and is headquartered in Basel, Switzerland.
Founded in 1896 and based in Basel, Switzerland, the group develops prescription medicines and runs a diagnostics business, selling its products across Europe, North and Latin America, Asia, Africa and Australia. Its drug portfolio covers oncology, immunology, neurology, ophthalmology and transplant care, while its laboratory arm offers in vitro tests for conditions such as cancer, diabetes and hepatitis, together with diagnostic instruments and digital health tools. The company also collaborates with Excalipoint Therapeutics to evaluate EXP011 in solid tumours that express DLL3.
In the fiscal year ended 31 December 2025, revenue reached CHF 63.4 billion, up 1.5% on the previous year, and net income came to CHF 12.9 billion. The group employs 103,249 people. Its shares also trade on SIX.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- Headquarters
- Grenzacherstrasse 124, 4070, Basel
- Employees
- 103,249
- Chief executive
- Thomas Schinecker
- Founded
- 1896
- Fiscal year
- January - December
- Listing
- ROP · SIX
- Indices
- SMI
- Currency
- CHF
- ISIN
- CH1499059983
- Website
- roche.com
Roche Holding and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Roche HoldingROP | Switzerland | $387.55B | 103,249 | 33.1% | 26.6 |
| NovartisNOVN | Switzerland | $301.99B | 75,267 | 34.0% | 32.1 |
| AstraZenecaAZN | United Kingdom | $286.82B | 96,100 | 25.8% | 26.5 |
| Novo NordiskNOVO.B | Denmark | $181.48B | 68,794 | 50.8% | 10.9 |
| SanofiSAN | France | $116.24B | 74,846 | 22.3% | 25.3 |
| GSKGSK | United Kingdom | $101.36B | 66,841 | 30.5% | 17.9 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
